Tracon Pharmaceuticals Inc.
22
0
1
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
9.1%
2 terminated/withdrawn out of 22 trials
88.9%
+2.4% vs industry average
5%
1 trials in Phase 3/4
88%
14 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
Role: collaborator
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
Role: lead
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Role: lead
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
Role: lead
A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer
Role: collaborator
Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
Role: lead
Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial
Role: lead
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
Role: lead
Trial of TRC105 and Sorafenib in Patients With HCC
Role: lead
Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC
Role: lead
A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Role: lead
Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
Role: lead
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
Role: lead
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Role: lead
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
Role: lead
TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma
Role: lead
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
Role: lead
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Role: lead
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
Role: lead
Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
Role: lead